Shenglian Bio Receives Approval for Live Pseudorabies Vaccine for Swine
Shenglian Bio has announced that its subsidiary, the Lanzhou branch, has received approval from the Ministry of Agriculture and Rural Affairs for its live pseudorabies vaccine for swine, strain JS-A1. This approval was granted in accordance with regulations including the "Regulations on the Administration of Veterinary Drugs" and the "Measures for the Administration of Veterinary Drug Product Approval Numbers." The company has been issued the veterinary drug product approval number, authorizing the production and distribution of this vaccine. This development signifies a key regulatory milestone for Shenglian Bio in the swine health sector. The vaccine targets the pseudorabies virus, a significant pathogen affecting pig populations globally. The approval process involved a thorough review by the Ministry, ensuring the vaccine meets established standards for safety and efficacy. Shenglian Bio's Lanzhou branch will now proceed with the manufacturing of the approved vaccine.
The approval of Shenglian Bio's live pseudorabies vaccine by China's Ministry of Agriculture and Rural Affairs represents a significant step in addressing a persistent animal health challenge. Pseudorabies virus poses substantial economic risks to the swine industry, impacting productivity and trade. This regulatory green light suggests the vaccine has met the stringent criteria for efficacy and safety, potentially offering a crucial tool for disease control. From a market perspective, this approval could enhance Shenglian Bio's competitive position and contribute to broader efforts in biosecurity within the agricultural sector. Looking ahead, the successful deployment and adoption of this vaccine will be critical in mitigating the impact of pseudorabies, underscoring the importance of ongoing research and development in veterinary pharmaceuticals.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.